← Back to Screener
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL)
Price$1.05
Favorite Metrics
Price vs S&P 500 (4W)-6.61%
All Metrics
Price vs S&P 500 (YTD)12.19%
10-Day Avg Trading Volume0.03M
3-Month Avg Trading Volume0.04M
52-Week High$1.40
13-Week Price Return15.05%
Year-to-Date Return15.05%
5-Day Price Return1.90%
Month-to-Date Return3.87%
Price vs S&P 500 (13W)12.19%
52-Week Low$0.65
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031 | — | — | — | — | $1.05 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
BriaCell Therapeutics is a clinical-stage biotechnology company developing cell-based immunotherapies for cancer. Its lead program, Bria-IMT, is in end-stage clinical trials for breast cancer, while pipeline candidate Bria-OTS targets breast and prostate cancer with personalized approaches. The company is pursuing combination therapy strategies through clinical collaborations to enhance treatment outcomes.